Merck's Tulisokibart Hits Key Milestones in Hidradenitis Suppurativa Study

Merck & Co., Inc. (ISIN US58933Y1055) reported positive results for its pipeline asset, tulisokibart. In a Phase 2b study evaluating the treatment in patients with moderate to severe hidradenitis suppurativa, Merck announced that tulisokibart met both primary and key secondary endpoints on September 30, 2026.

The news contributes to Merck's efforts to expand its portfolio beyond established oncology products. The company generated $16.61 billion in revenue during the second quarter of 2026, up 5.10 percent from the same period a year earlier, according to Yahoo Finance.

Analyst expectations are divided, with Bernstein reiterating a Market Perform rating and a $105 price target on September 29, 2026. However, Berenberg, Guggenheim, and Wolfe Research increased their targets for Merck stock.